Sugi Predict

Sugi Predict / Targets / GRM4

GRM4

Metabotropic glutamate receptor 4 · Q14833 · GRM4 on Sugi Atlas →

92,381 patent compounds predicted against GRM4, 45,255 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL133544 SCHEMBL133544 0.50 20/20
SCHEMBL56509 SCHEMBL56509 0.57 19/20
SCHEMBL56829 SCHEMBL56829 0.53 19/20
SCHEMBL56510 SCHEMBL56510 0.60 17/20
SCHEMBL56830 SCHEMBL56830 0.56 15/20
SCHEMBL123148 SCHEMBL123148 0.50 15/20
SCHEMBL100305 SCHEMBL100305 1.00 14/20
SCHEMBL179741 SCHEMBL179741 1.00 8/20
SCHEMBL160783 SCHEMBL160783 0.54 8/20
SCHEMBL129688 SCHEMBL129688 0.51 8/20
SCHEMBL179722 SCHEMBL179722 0.47 8/20
SCHEMBL180209 SCHEMBL180209 0.45 8/20
SCHEMBL59793 SCHEMBL59793 0.44 8/20
SCHEMBL60473 SCHEMBL60473 0.44 8/20
SCHEMBL62221 SCHEMBL62221 0.44 8/20
SCHEMBL158602 SCHEMBL158602 0.41 8/20
SCHEMBL145957 SCHEMBL145957 0.58 7/20
SCHEMBL57902 SCHEMBL57902 0.47 7/20
SCHEMBL57903 SCHEMBL57903 0.47 7/20
SCHEMBL179801 SCHEMBL179801 1.00 6/20

Clinical trials — most relevant to GRM4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine PHASE4COMPLETED
Pilot Study: Postoperative Pain Reduction by Pre Emptive N-Acetylcysteine PHASE4COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders PHASE3RECRUITING
Memantine for Refractory OCD Patients PHASE3UNKNOWN
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK) PHASE2/PHASE3RECRUITING
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial PHASE2/PHASE3NOT_YET_RECRUITING
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation PHASE3COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder PHASE2COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia PHASE2UNKNOWN
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia PHASE2COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders PHASE2COMPLETED
TRPM8 Activators for Peripheral Neuropathy PHASE2ACTIVE_NOT_RECRUITING
Brain Imaging, Genetics and Treatment for Major Depression PHASE1WITHDRAWN
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203 PHASE1COMPLETED
Antidepressant Effects of NR2B in Major Depression PHASE1COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia PHASE1COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial PHASE1COMPLETED
A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers PHASE1COMPLETED
Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain PHASE1COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response PHASE1RECRUITING
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine EARLY_PHASE1COMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX nanCOMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease nanCOMPLETED
Acamprosate: Genes Associated With Response nanCOMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Metabotropic Receptors For Glutamate Type 3 In Parkinson's nanUNKNOWN
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy nanUNKNOWN
Imaging mGluR5 and Synaptic Density in Psychiatric Disorders nanCOMPLETED
Sleep/Wake Cycle and Depression: An Imaging and Treatment Study nanCOMPLETED
Epigenetic and Neurochemical Correlates of Bipolar Disorder nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a GRM4 binder may also engage these)

ProteinNameSimilarity
Q68EF4 — 1.000 Q68EF4 →
Q1ZZH0 — 0.999 Q1ZZH0 →
P31423 — 0.998 P31423 →
Q5NCH9 — 0.981 Q5NCH9 →
P35349 — 0.981 P35349 →
GRM6 Metabotropic glutamate receptor 6 0.976 landscape →
Q863I4 — 0.971 Q863I4 →
GRM8 Metabotropic glutamate receptor 8 0.970 landscape →
P70579 — 0.966 P70579 →
Q5RDQ8 — 0.965 Q5RDQ8 →
P47743 — 0.965 P47743 →
Q68ED2 — 0.961 Q68ED2 →
P35400 — 0.956 P35400 →
GRM7 Metabotropic glutamate receptor 7 0.953 landscape →
Q9R1M7 — 0.949 Q9R1M7 →
Q61088 — 0.948 Q61088 →
A2AIR5 — 0.946 A2AIR5 →
Q9ULV1 — 0.945 Q9ULV1 →
GRIN3A Glutamate receptor ionotropic, NMDA 3A 0.944 landscape →
Q9QZH0 — 0.943 Q9QZH0 →
Q9IA05 — 0.941 Q9IA05 →
Q62645 — 0.938 Q62645 →
Q96BD0 — 0.937 Q96BD0 →
Q99N01 — 0.936 Q99N01 →
Q00960 — 0.936 Q00960 →
TRPM2 Transient receptor potential cation channel subfamily M member 2 0.935 landscape →
Q91YD4 — 0.935 Q91YD4 →
GRIN2B Glutamate receptor ionotropic, NMDA 2B 0.935 landscape →
Q91WC3 — 0.935 Q91WC3 →
Q8K415 — 0.935 Q8K415 →